Pharmacodynamic Response of the MET/HGF-Receptor to Small Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays

PURPOSE: Rational development of targeted MET inhibitors for cancer treatment requires a quantitative understanding of target pharmacodynamics, including molecular target engagement, mechanism of action, and duration of effect. METHODS: Sandwich immunoassays and specimen-handling procedures were dev...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Srivastava, Apurva K, Hollingshead, Melinda G., Weiner, Jennifer, Navas, Tony, Evrard, Yvonne A., Khin, Sonny, Ji, Jiuping, Zhang, Yiping, Borgel, Suzanne, Pfister, Thomas D, Kinders, Robert J., Bottaro, Donald P, Linehan, W Marston, Tomaszewski, Joseph E, Doroshow, James H, Parchment, Ralph E
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7802886/
https://ncbi.nlm.nih.gov/pubmed/27001313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2323
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi